ANNOVIS BIO INC. COMMON STOCK
5.1600
26-December-24 16:30:01
15 minutes delayed
Stocks
+0.1500
+2.99%
Today's range
4.8600 - 5.2500
ISIN
N/A
Source
NYSE
-
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Announces New Publication in a Peer-Reviewed Journal
21 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
13 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
09 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
06 May 2024 07:30:00 By Nasdaq GlobeNewswire
-
29 Apr 2024 10:10:00 By Nasdaq GlobeNewswire
-
02 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
-
01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire
-
20 Mar 2024 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
-
14 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
-
30 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
24 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio to Participate in the 139th Yale CEO Summit
11 Dec 2023 13:00:00 By Nasdaq GlobeNewswire
-
05 Dec 2023 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Appoints Andrew Walsh as Vice President Finance
01 Dec 2023 07:30:00 By Nasdaq GlobeNewswire
-
27 Nov 2023 07:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
08 Nov 2023 17:00:00 By Nasdaq GlobeNewswire
-
12 Oct 2023 08:02:38 By Nasdaq GlobeNewswire
-
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 May 2023 07:00:01 By Nasdaq GlobeNewswire